Cytokinetics, Incorporated
CYTK · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $18 | $8 | $95 | $70 |
| % Growth | 145.3% | -92% | 34.3% | – |
| Cost of Goods Sold | $339 | $330 | $241 | $160 |
| Gross Profit | -$321 | -$323 | -$146 | -$90 |
| % Margin | -1,737.2% | -4,284.1% | -154.6% | -127.1% |
| R&D Expenses | $339 | $330 | $241 | $160 |
| G&A Expenses | $215 | $174 | $178 | $97 |
| SG&A Expenses | $215 | $174 | $178 | $97 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$339 | -$330 | -$241 | -$160 |
| Operating Expenses | $215 | $174 | $178 | $97 |
| Operating Income | -$536 | -$496 | -$324 | -$186 |
| % Margin | -2,902.7% | -6,589.7% | -342.8% | -264.5% |
| Other Income/Exp. Net | -$53 | -$30 | -$65 | -$29 |
| Pre-Tax Income | -$590 | -$526 | -$389 | -$215 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$590 | -$526 | -$389 | -$215 |
| % Margin | -3,191.1% | -6,988.6% | -411.2% | -305.7% |
| EPS | -5.26 | -5.45 | -4.33 | -2.8 |
| % Growth | 3.5% | -25.9% | -54.6% | – |
| EPS Diluted | -5.26 | -5.45 | -4.33 | -2.8 |
| Weighted Avg Shares Out | 112 | 97 | 90 | 77 |
| Weighted Avg Shares Out Dil | 112 | 97 | 90 | 77 |
| Supplemental Information | – | – | – | – |
| Interest Income | $52 | $28 | $11 | $0 |
| Interest Expense | $87 | $58 | $51 | $29 |
| Depreciation & Amortization | $10 | $12 | $8 | $10 |
| EBITDA | -$493 | -$457 | -$329 | -$176 |
| % Margin | -2,671.2% | -6,064.9% | -348.2% | -250.4% |